Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among over-the-counter (OTC) drugs, loperamide has recently emerged for its potential of misuse and cardiotoxicity issues. Hence, we aimed here at assessing the loperamide-related cases being reported to the EMA's EudraVigilance (EV) database. METHODS: All spontaneous EV reports relating to loperamide misuse/abuse/dependence/withdrawal and cardiotoxicity issues were here retrieved, performing a descriptive analysis. FINDINGS: During the years 2005-2017, EV collected a number of 1,983 (out of a total of 7,895; 25.11%) loperamide-related misuse/abuse/dependence/withdrawal adverse drug reaction (ADR) reports, with a progressively increasing trend since 2014. Most cases were classified as drug use disorder (37.4%) or intentional overdose (25.4%). Loperamide was used on its own in 41.9% of cases; remaining, polydrug, cases included antidepressants; benzodiazepines; and other OTCs. Some 1,085 (1,085/7,895 = 13.7%) cardiovascular ADRs were reported, being conduction abnormalities and EKG alterations the most frequently identified. CONCLUSIONS: EV data may support the levels of concern relating to loperamide potential of abuse and associated cardiotoxicity issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Its extended-release (XR) formulation may be less frequently misused and abused, due to the delayed (by approximately 3 h) and blunted (by approximately 67%) serum peak; the tablet coating may also make snorting of the crushed tablets quite problematic (47).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [47]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
P-glycoprotein Inhibition for Optimal Drug Delivery
Amin, M. L. (2013) · Drug Target Insights · doi:10.4137/dti.s12519 · Cited by 624
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Loperamide: a pharmacological review.
Baker, D. E. (2007) · PubMed · Cited by 242
Over-the-counter medicine abuse – a review of the literature
Cooper, R. J. (2013) · Journal of Substance Use · doi:10.3109/14659891.2011.615002 · Cited by 241
Manchikanti, L. (2006) · PubMed · Cited by 186
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
Daniulaityte, R., Carlson, R. G., Falck, R. S., Cameron, D., Perera, S., Chen, L., & Sheth, A. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.003 · Cited by 136
Clinical Review: Loperamide Toxicity
Wu, P. E., & Juurlink, D. N. (2017) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2017.04.008 · Cited by 127
‘Pharming’: the abuse of prescription and over-the-counter drugs in teens
Levine, D. A. (2007) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32814b09cf · Cited by 101
Loperamide Abuse Associated With Cardiac Dysrhythmia and Death
Eggleston, W. D., Clark, K., & Marraffa, J. M. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.03.047 · Cited by 101
Cited by
Cardiovascular Complications of Opioid Use
Krantz, M. J., Palmer, R. B., & Haigney, M. C. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.002 · Cited by 158
New/emerging psychoactive substances and associated psychopathological consequences
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021) · Psychological Medicine · doi:10.1017/s0033291719001727 · Cited by 119
“Cytochrome inhibitors, such as cimetidine, omeprazole and grapefruit juice, as well as P-glycoprotein inhibitors, such as quinidine-quinine and pepper, may be concomitantly used to raise the drug blood levels (Baker, 2007; Schifano and Chiappini, 2018b) (Table 1).”
BackgroundSelf-citationSex and Gender Differences in the Effects of Novel Psychoactive Substances
Fattore, L., Marti, M., Mostallino, R., & Castelli, M. P. (2020) · Brain Sciences · doi:10.3390/brainsci10090606 · Cited by 78
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00046 · Cited by 55
Self-citationAlgarni, M., Hadi, M. A., Yahyouche, A., Mahmood, S., & Jalal, Z. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00350-7 · Cited by 67
“Schifano F, Chiappini S.”
BackgroundMethodInfluentialPharmacological Aspects of Over-the-Counter Opioid Drugs Misuse
Sobczak, Ł., & Goryński, K. (2020) · Molecules · doi:10.3390/molecules25173905 · Cited by 46
“However, regardless of consumed amount, loperamide seems to be without an analgesic effect [76,89].”
BackgroundChiappini, S., Schifano, F., Corkery, J., & Guirguis, A. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959615 · Cited by 47
Self-citationChiappini, S., Vickers‐Smith, R., Guirguis, A., Corkery, J., Martinotti, G., Harris, D. R., & Schifano, F. (2022) · Pharmaceuticals · doi:10.3390/ph15060675 · Cited by 46
“It would have been interesting, considering that the pharmacodynamic properties of drugs can change by using mega doses, and interactions between molecules could lead to unpredictable consequences in terms of psychotropic effects that might have justified their use, as, for example, in the case of the antidiarrhoeic d…”
BackgroundSelf-citationChiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
Self-citationThe e-psychonaut drugs’ psychopharmacology
Schifano, F., Chiappini, S., Corkery, J., Scherbaum, N., & Guirguis, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.008 · Cited by 34
“However, at high dosages (50–800 mg), it is associated with an opiate-like euphoric state (‘lope high’; ‘poor man’s methadone’; for an overview, see [44]).”
BackgroundSelf-citationGhalandari, N., Crijns, H. J. M. J., Bergman, J. E. H., Dolhain, R. J. E. M., van Puijenbroek, E., & Hazes, J. M. W. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15471 · Cited by 24
“This pharmacovigilance database is used for collecting the reports of suspected adverse drug reactions (ADRs) to medications that have been authorized by the European Medicines Agency (EMA).(23) The purpose of this database, which was launched in 2001, is to enable the early detection of possible safety signals from m…”
MethodLoperamide: A Readily Available but Dangerous Opioid Substitute
White, C. M. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1449 · Cited by 21
The Benzydamine Experience: A Systematic Review of Benzydamine Abuse
Chiappini, S., Miuli, A., Mosca, A., Pettorruso, M., Guirguis, A., John, M. C., Martinotti, G., Giannantonio, M. D., & Schifano, F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210113151136 · Cited by 20
“Remaining OTC drugs being reported in this age-group include: loperamide [31]; dextromethorphan; pseudoephedrine; and mixtures of promethazine and”
Self-citationComing Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Self-citationTanibuchi, Y., Omiya, S., Usami, T., & Matsumoto, T. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12415 · Cited by 14
Cutaneous Adverse Drug Reaction
Aboud, D. M. A., Nessel, T. A., & Hafsi, W. (2021) · StatPearls · Cited by 13
The safety of available treatment options for short bowel syndrome and unmet needs
Pironi, L., Raschi, E., & Sasdelli, A. S. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1940947 · Cited by 17
“However, cases of TdP have been described during the opioid crisis, following overdoses when combined with a P-glycoprotein inhibitor, also considering that loperamide is an extraordinarily potent hERG blocker [35,36].”
BackgroundVera, G., Girón, R., Martín, M. I., & Abalo, R. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13621 · Cited by 14
Ramos, C., Guirguis, A., Smeeton, N., Zaman, H., Felice, A. M., Bancroft, S., Gittins, R., Hawksworth, G., Corkery, J., & Schifano, F. (2020) · Brain Sciences · doi:10.3390/brainsci10030142 · Cited by 14
“Given that community pharmacists are potentially the first point-of-contact able to identify a repeat supply issue, their links with prescribers/clinicians should be enhanced for appropriate referrals to be made, thus allowing individuals to have more access to treatment services [88].”
BackgroundSelf-citationChiappini, S., Ceci, F., Mosca, A., Carlo, F. D., Burkauskas, J., Pettorruso, M., Martinotti, G., Guirguis, A., Corkery, J., Scherbaum, N., et al. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220714104231 · Cited by 13
“…diphenhydramine and dimenhydrinate [3, 14, 15]; ii) syrups based on codeine and/or promethazine [3, 16-18]; iii) dextromethorphan cough syrups [3, 11, 19]; iv) drugs based on ephedrine and pseudoephedrine [3, 20]; v) loperamide [3, 21, 22]; vi) and benzydamine-based anti-inflammatories [3, 23, 24].”
Self-citationManagement of overdoses of loperamide, gabapentin, and modafinil: a literature review
Reinert, J. P., & Dunn, R. L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1657830 · Cited by 10
Loperamide-induced cardiotoxicity: a case overlooked?
Iqbal, S., Fayyaz, S. M., Saeed, Y., & Aqeel, M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243325 · Cited by 8
Una aproximación al panorama actual de las nuevas formas de consumo de drogas
Folgar, M. I., & Árias, F. (2022) · Adicciones · doi:10.20882/adicciones.1787 · Cited by 17
“…a potent mu-opioid receptor agonist and when consumed in large quantities (more than 50 mg) produces euphoric effects, central nervous system depression, possibly stronger initial euphoria followed by CNS depression and cardiotoxicity (Eggleston, Clark & Marraffa, 2017; Schifano & Chiappini, 2018).”
BackgroundInfluentialSubstances led to Psychosis: A Systematic Review
Karimi, I., & Pooyanmehr, N. (2024) · The Open Psychology Journal · doi:10.2174/0118743501297735240510161825 · Cited by 6
Lu, H. R., Damiano, B. P., Kreir, M., Rohrbacher, J., van der Linde, H. J., Saidov, T. A., Teisman, A. C. H., & Gallacher, D. J. (2023) · Biomolecules · doi:10.3390/biom13091355 · Cited by 8
A Qualitative Analysis of First-Hand Accounts of Diphenhydramine Misuse Available on YouTube
Dourron, H. M., Copes, H., Vedre-Kyanam, A., Reyes, D., Gossage, M., Sweat, N. W., & Hendricks, P. S. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2251985 · Cited by 6
“Many substances with diverse pharmacological profiles including benzydamine, loper-amide (Schifano and Chiappini 2018), and OTC cough medication (e.g., dextromethorphan) have been mis-used in this manner (Schifano et al. 2021).”
Over-the-counter medications encountered in the postmortem pediatric population from 2010–2020
Swatek, J. L., Marco, S., & Midthun, K. M. (2024) · Journal of Analytical Toxicology · doi:10.1093/jat/bkae042 · Cited by 5
Barakat, M. M., Akour, A. A., Malaeb, D. N., Cherri, S., Safadi, W. A., Safadi, A. A., & Wazaify, M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20146400 · Cited by 4
A Rising Concern of Loperamide Abuse: A Case Report on Resulting Cardiac Complications
Sapra, A., Bhandari, P., Gupta, S. K., Kraleti, S. S., & Bahuva, R. (2019) · Cureus · doi:10.7759/cureus.6314 · Cited by 5
“Studies have reported misusers describing their experiences, like “lope highs” after large consumptions of the medicine as ”better than any oxycodone” [8].”
BackgroundNon-medical use of loperamide in the UK and the USA
Webb, N. E., Wood, D. M., Black, J. C., Amioka, E., Dart, R. C., & Dargan, P. I. (2019) · QJM · doi:10.1093/qjmed/hcz215 · Cited by 4
The Risks of “Getting High” on Over-the-Counter Drugs during Pregnancy
Ősz, B.-E., Ștefănescu, R., Sălcudean, A., Jîtcă, G., & Vari, C.-E. (2024) · Scientia Pharmaceutica · doi:10.3390/scipharm92010007 · Cited by 4
“Between 2005–2017, approximately 2000 cases of adverse drug reaction related to lop-eramide misuse, abuse, addiction, or withdrawal were reported in the European Medicines Agency (EMA) EudraVigilance database [38].”
BackgroundEffect of loperamide on heart rhythm: Randomized, double-blind, controlled study in healthy adults
Cirillo, I., Ariyawansa, J., Ali, S. R., & Atillasoy, E. O. (2024) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2024.100006 · Cited by 3
AMBRIN, Z., Vineetha, K., & Shabaraya, A. R. (2023) · International Journal of Biological and Pharmaceutical Sciences Archive · doi:10.53771/ijbpsa.2023.6.2.0116 · Cited by 3
Coppiano, L. S., & May, D. W. (2019) · Side effects of drugs annual · doi:10.1016/bs.seda.2019.08.009 · Cited by 3
Chiappini, S., Guirguis, A., Corkery, J., & Schifano, F. (2020) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2020.20208538 · Cited by 56
Self-citationMethadone, synthetic opioids and torsades de pointes
Krantz, M. J., & Haigney, M. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821446-6.00004-3 · Cited by 1
Donkor, C. M. Y. A., Aryee-Boi, J., Osazuwa, I. R., Afflu, F. K., & Alexis, A. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-72617-1_2
Olive, M. F. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738648107.793578358
Pattern of Cutaneous Adverse Drug Reactions in a Tertiary Care Hospital of Bihar
Arya, A. K., Mohan, P. L., Kumar, M., Hameed, S., & Sinha, P. R. (2023) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2023.v83i02.012
Chiappini, S., Orsolini, L., Corkery, J., Guirguis, A., Mosca, A., Arillotta, D., Martinotti, G., & Schifano, F. (2025) · Brain Sciences · doi:10.3390/brainsci15111177
“…that may not be captured in clinical trials, e.g., the possible misuse of medications such as the over-the-counter anti-diarrhoeal loperamide [21] or the antiepileptic drug pregabalin [22], then leading to specific strategies and interventions to reduce the possible related risks in special…”
Self-citationAlgarni, M., Hadi, M. A., Yahyouche, A., Mahmood, S., & Jalal, Z. (2021) · Figshare · doi:10.6084/m9.figshare.16614560
Silencing without clearing: pharmacological modulation of the SASP in aging and disease
Fresser, L., Chrienová, Ž., Gebrt, J., Olekšák, P., Kuča, K., & Nepovimová, E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1911529
“Loperamide’s use at higher-than-therapeutic doses carries significant cardiac and neurological risks (Schifano and Chiappini, 2018; White, 2019; Wu and Juurlink, 2017), which would substantially complicate its repurposing for chronic senomorphic applications.”
Metadata
- Authors
- Schifano, F., & Chiappini, S.
- Affiliations
- University of Hertfordshire (GB)
- Corresponding author
- Chiappini, Stefania
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-10-04
- Volume
- 13
- Issue
- 10
- Pages
- e0204443
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6171858
- OpenAlex
- W2895091112
- Cited by
- 44
- References
- 52
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 8
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- loperamide, drug abuse, drug addiction, withdrawal, cardiotoxicity, adverse drug reactions, over-the-counter drugs, EudraVigilance, pharmacovigilance, intentional overdose, drug use disorders, polydrug use, cardiovascular adverse events, electrocardiographic abnormalities
- MeSH terms
- Drug Misuse, Adolescent, Adult, Cardiovascular Diseases, Nonprescription Drugs, Europe, Female, Humans, Loperamide, Male, Middle Aged, Polypharmacy, Substance-Related Disorders, Young Adult, Pharmacovigilance, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.